Department of Genetics, F76000 and Normandie Univ, UNIROUEN, Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Rouen, France.
Department of Genetics, F14000 and Normandie Univ, Normandy Centre for Genomic and Personalized Medicine, Caen University Hospital, Caen, France.
Eur J Hum Genet. 2018 Nov;26(11):1597-1602. doi: 10.1038/s41431-018-0207-2. Epub 2018 Jul 2.
We have developed and validated for the diagnosis of inherited colorectal cancer (CRC) a massive parallel sequencing strategy based on: (i) fast capture of exonic and intronic sequences from ten genes involved in Mendelian forms of CRC (MLH1, MSH2, MSH6, PMS2, APC, MUTYH, STK11, SMAD4, BMPR1A and PTEN); (ii) sequencing on MiSeq and NextSeq 500 Illumina platforms; (iii) a bioinformatic pipeline that includes BWA-Picard-GATK (Broad Institute) and CASAVA (Illumina) in parallel for mapping and variant calling, Alamut Batch (Interactive BioSoftware) for annotation, CANOES for CNV detection and finally, chimeric reads analysis for the detection of other types of structural variants (SVs). Analysis of 1644 new index cases allowed the identification of 323 patients with class 4 or 5 variants, corresponding to a 20% disease-causing variant detection rate. This rate reached 37% in patients with Lynch syndrome, suspected on the basis of tumour analyses. Thanks to this strategy, we detected overlapping phenotypes (e.g., MUTYH biallelic mutations mimicking Lynch syndrome), mosaic alterations and complex SVs such as a genomic deletion involving the last BMPR1A exons and PTEN, an Alu insertion within MSH2 exon 8 and a mosaic deletion of STK11 exons 3-10. This strategy allows, in a single step, detection of all types of CRC gene alterations including SVs and provides a high disease-causing variant detection rate, thus optimizing the diagnosis of inherited CRC.
我们开发并验证了一种用于遗传性结直肠癌(CRC)诊断的大规模平行测序策略,该策略基于:(i)快速捕获十个与CRC 的孟德尔形式相关的基因(MLH1、MSH2、MSH6、PMS2、APC、MUTYH、STK11、SMAD4、BMPR1A 和 PTEN)的外显子和内含子序列;(ii)在 MiSeq 和 NextSeq 500 Illumina 平台上进行测序;(iii)一种生物信息学管道,包括 BWA-Picard-GATK(Broad Institute)和 CASAVA(Illumina),用于映射和变异调用,Alamut Batch(Interactive BioSoftware)用于注释,CANOES 用于 CNV 检测,最后,用于检测其他类型结构变异(SVs)的嵌合读取分析。对 1644 个新的索引病例进行分析,确定了 323 名具有 4 类或 5 类变异的患者,对应的致病变异检出率为 20%。在基于肿瘤分析怀疑患有林奇综合征的患者中,这一比率达到了 37%。得益于这一策略,我们检测到了重叠表型(例如,MUTYH 双等位基因突变模拟林奇综合征)、镶嵌性改变和复杂的 SVs,如涉及最后 BMPR1A 外显子和 PTEN 的基因组缺失、MSH2 外显子 8 内的 Alu 插入以及 STK11 外显子 3-10 的镶嵌性缺失。这种策略可以在单个步骤中检测包括 SVs 在内的所有类型的 CRC 基因改变,并提供高的致病变异检出率,从而优化遗传性 CRC 的诊断。